Tinzaparin in Long-term Treatment of Deep Venous Thrombosis  by Daskalopoulos, M.E. et al.
Eur J Vasc Endovasc Surg 34, 353e354 (2007)
doi:10.1016/j.ejvs.2007.04.012, available online at http://www.sciencedirect.com onEDITORIAL
Tinzaparin in Long-term Treatment of Deep Venous ThrombosisIn recent years low molecular weight heparins
(LMWHs) have extensively and successfully replaced
unfractionated heparin (UFH) in both thrombopro-
phylaxis and initial treatment of venous thrombo-
embolism (VTE). However, the use of vitamin K
antagonists remains the standard long-term VTE
treatment. Current research interest is focused on
the evaluation of LMWHs in replacing oral anticoag-
ulants (OAs) in different patient populations, admin-
istered for 3 to 6 months.
LMWHs that were empirically used for many years
as an alternative to UFH for the long-term secondary
VTE prophylaxis in specific conditions, such as an in-
creased risk of haemorrhage, complications from pre-
vious OA use, pregnancy and other contraindications
for vitamin K antagonists, inability or unwillingness
for regular laboratory monitoring or for administra-
tion of oral medication, have currently become every-
day clinical practice. Data extracted from such series
of patients provide evidence that LMWHs are possi-
bly an effective alternative to vitamin K antagonists
in the long-term treatment of VTE.
Since 1987 several retrospective studies evaluated
the long-term administration of LMWHs. They all
conclude that LMWHs are an alternative to conven-
tional therapy (UFH and OAs) in DVT secondary pre-
vention. More recent research prospectively evaluated
the efficacy and safety of LMWH therapy as an alter-
native to vitamin K antagonists in the long-term man-
agement of VTE. Nine randomised trials evaluated
a LMWH versus conventional therapy in the long-
term treatment of venous thrombosis.1,2 Different
LMWHs (enoxaparin, dalteparin, nadroparin, bemi-
parin), but not tinzaparin, were administered most
commonly for 3 months to cancer patients or to
a broad spectrum of patients, according to various
protocols. All nine category I and II prospective rand-
omised trials were in favour of LMWHs.1,2 However,
LMWHs are distinct non-interchangeable compounds
requiring individual testing.3
The effectiveness and safety of tinzaparin was
more recently evaluated compared with ‘‘usual care’’
(intravenous UFH followed by acenocoumarol), in the1078–5884/000353+ 02 $32.00/0  2007 Published by Elsevier Ltd olong-term treatment of acute proximal deep venous
thrombosis (DVT). The first open-label, prospective,
randomized clinical study was published by our
group in the European Journal of Vascular and Endovas-
cular Surgery.4 The results of this study were con-
firmed by a more recent larger study by the LITE
Trial Investigators; two articles were published study-
ing the balance of benefits and harms of self-managed
long-term tinzaparin therapy of DVT,5 and the effec-
tiveness of the LMWH in a subgroup of cancer
patients with acute proximal DVT.6
The above studies4e6 agree that tinzaparin is a safe
and effective alternative to the ‘‘usual care’’. However,
some differences in those studies merit mentioning;
treatment was administered for 3 months in the
LITE Trial studies,5,6 and for 6 months in our study4;
6 months was considered as a more appropriate
period for treating proximal thromboses, especially
in patients with co-morbidities predisposing to VTE
and VTE recurrence.4 In the articles by the LITE Trial
Investigators5,6 assessments were performed at entry
and at 3 months, while the 12 month follow-up was
performed by telephone and included questionnaires
about objectively documented recurrent VTE or death.
In contrast, in our study4 entry and scheduled assess-
ments at 1, 3, 6 and 12 months included clinical exam-
ination, blood tests (full blood count, urea, creatinine,
electrolytes, liver function tests, clotting profile and
thrombophilia screening when indicated) and color
duplex imaging. In the LITE Trial studies5,6 no de-
tailed information is provided regarding the criteria
used to identify recurrent DVT. In our study,4 throm-
bus extent was quantitatively monitored by an ultra-
sonographic scoring system (clot volume score); clot
regression was significant in both treatment groups
over time. However, recanalisation was more ex-
tended with tinzaparin from 3 months onwards
(P< 0.02), without an increased extent of ultrasono-
graphically-identified venous reflux.4 These outcomes
were not included in the LITE Trial studies. The
cancer subgroup study6 showed that tinzaparin was
associated with less VTE recurrence than the ‘‘usual
care’’ at 12 months (P¼ 0.044), while there was non behalf of European Society for Vascular Surgery.
354 Editorialsignificant difference in the safety between the two
treatments. The other two studies4,5 showed that tin-
zaparin was at least as effective but safer than the
‘‘usual care’’. In our study4 the composite incidence
of major events (mortality, DVT recurrence, pulmo-
nary embolism, major bleeding, heparin-induced
thrombocytopenia) was in favour of tinzaparin
(P¼ 0.035). In the main LITE Trial study5 all bleeding
complications occurred less frequently in patients re-
ceiving LMWH (P¼ 0.011). The safety of tinzaparin
is an important issue, especially for specific sub-
groups, including elderly, pregnant women and chil-
dren; specifically designed studies are needed to
address this issue.1 Furthermore, in our study4
a cost analysis favoured tinzaparin (with a significant
decrease in hospitalisation costs), even excluding the
cost of hospitalisations due to complications (signifi-
cantly more in the ‘‘usual care’’ group).
Further follow-up results at 18, 24, 30, 36 and 42
months available to us, show not only the long-term
effectiveness of tinzaparin in DVT secondary prophy-
laxis, but also its superiority over the conventional
treatment in the development of post-thrombotic
syndrome and the formation of venous ulcers.
Despite the differences between the LITE Trials In-
vestigators studies5,6 and our study4 they all support
the current knowledge that LMWHs are possibly at
least as effective but safer than OAs in the long-term
treatment of VTE, enhancing thrombus lysis and
achieving earlier recanalisation of the DVT. These
studies provide complementary evidence that tinza-
parin is another effective and safe LMWH that should
be added in the therapeutic armory for patients with
acute proximal DVT.
Recommendations for future practice should result
from adequately designed prospective randomised
controlled clinical trials and ‘‘head-to-head’’Eur J Vasc Endovasc Surg Vol 34, September 2007comparisons between different LMWHs. These trials
should address long-term VTE treatment for all pa-
tients and specific subgroups (e.g. patients at high
risk of bleeding, contraindications for OAs and diffi-
culties in compliance with standard therapy).
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